Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection

  • Charman, Susan (Primary Chief Investigator (PCI))
  • Avery, Vicky (Chief Investigator (CI))
  • Best, Wayne (Partner Investigator (PI))
  • Chatelain, Eric (Partner Investigator (PI))
  • Keenan, Martine (Partner Investigator (PI))
  • Kelly, John Morrison (Partner Investigator (PI))

Project: Research

Project Description

This project will develop new tools and approaches to enhance drug discovery for Chagas disease, a serious, chronic illness endemic in countries of poverty and poorly treated by available drugs. Through the strategic application of these new tools, we will identify new drug candidates suitable for further development.
StatusFinished
Effective start/end date6/01/15 → 30/06/17

Funding

  • Australian Research Council (ARC): AUD507,000.00
  • DNDi Drugs for Neglected Diseases Initiative: AUD1,306,535.00
View all
View less

Related content

Research Output

Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage

Research output: Contribution to journal › Article › Research › peer-review